The University of Pittsburgh Cancer Institute (UPCI) proposes to continue to conduct a Specialized Program of Research Excellence (SPORE) in Lung Cancer. The overall goals of the UPCI Lung Cancer SPORE are to improve lung cancer detection, improve lung cancer treatment, and identify tobacco exposed individuals at highest risk for lung cancer, The SPORE program will consist of four major translational Research Projects in lung cancer, three Research Cores, an Administrative Core, a Developmental Research Program, and a Career Development Program. The UPCI Lung Cancer SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co-investigators in basic, population, and clinical science. It is also organ-specific in its approach and all projects will test hypotheses about lung cancer biology, susceptibility, detection, prevention, or treatment. The UPCI SPORE will carry out the directive to translate its findings within five years to human populations by using new knowledge to carry out interventions in humans and to determine the biological basis for observations made in patients with lung cancer, or in individuals at high risk for lung cancer. The long-term goal of the UPCI SPORE is to conduct clinical trials based on research results from its translational research projects that will serve as the basis for improving the outcome of patients diagnosed with lung cancer and to define new biological tools that will be useful in identifying asymptomatic lung cancer. The four main Projects are: (1) Selective Targeting of Estrogen Pathways in Lung Cancer Using Biomarkers; (2) Vitamin D Modulation of Inflammation and Lung Cancer Risk; (3) Lung Cancer Risk Prediction in the Pittsburgh Lung Screening Study (4) Targeting Neutrophil Elastase in Lung Cancer. The three Research Cores will assist the main research Projects, Developmental Research Projects, and Career Development Investigators in carrying out lung cancer translational research. The Research Cores are Clinical Core (Core B), Tissue and Blood Bank Core (Core C), and Biostatistics/Bioinformatics Core (Core D). The Administrative Core (Core A) will provide scientific and fiscal oversight for the program. UPCI SPORE investigators will work together as a team to meet the goals of the program and will also interact with translational investigators from other SPOREs and Cancer Centers, the NCI Program Office, and other co-operative groups to improve outcomes for lung cancer patients.

Public Health Relevance

The goal of this application is to use a multi-disciplinary approach to tackle the problem of poor outcomes in lung cancer, a deadly disease with only a 15% 5-year survival rate. We intend to improve outcomes for lung cancer patients by identifying new ways to treat the disease that are based on the biology of the individual patient's tumor and new ways to predict risk and prevent lung cancer based on an individual's genetics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-15
Application #
8917099
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ujhazy, Peter
Project Start
2001-06-01
Project End
2017-08-31
Budget Start
2015-09-01
Budget End
2017-08-31
Support Year
15
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Hopkins, Kathleen G; Ferson, Peter F; Shende, Manisha R et al. (2017) Prospective study of quality of life after lung cancer resection. Ann Transl Med 5:204
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363

Showing the most recent 10 out of 191 publications